PZP

Across TCGA pan-cancer cohorts, PZP RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PZP’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PZP RNA is repressed in tumor relative to normal tissue. In most cancer types PZP is over-expressed in tumor, although a few such as LIHC and LUSC show the opposite, repressed pattern.

LIHC, LUSC, and LUAD are the cancer types where PZP tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PZP RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−4.558	<.001	9	view →
LUSC	Female	II,III,IV	−1.287	<.001	8	view →
LUAD	All	III,IV	−0.978	<.001	8	view →
KICH	Female	All	−0.301	<.001	7	view →
BRCA	All	III,IV	−0.365	<.001	6	view →
KIRC	All	All	+0.119	<.001	6	view →
KIRP	All	All	−0.100	<.001	6	view →
COAD	Female	All	−0.046	.011	4	view →
CHOL	All	All	−3.136	.001	3	view →
BLCA	Male	All	−0.265	<.001	3	view →
READ	Female	All	−0.120	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PZP–LIHC

Open the LIHC breakdown →